Skip to main content
Premium Trial:

Request an Annual Quote

Not Convinced

In the Financial Times, a Glasgow general practitioner writes that the theory of personalized medicine is "nice" but that she doesn't "buy it." The GP, Margaret McCartney, says that "most genetic information does not give us clear-cut answers" as genes don't work in isolation from environment and that there is a lack of treatment, personalized or not, for many diseases. "My worry is that the use of genetic risk assessments to direct treatment will produce more dilemmas rather than less," McCartney writes. "Many of these conundrums will rest on our ability to assess and judge our risk of disease — and our abilities to prevent it."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.